Cargando…
Pharmacokinetics of the Monoclonal Antibody MHAA4549A Administered in Combination With Oseltamivir in Patients Hospitalized With Severe Influenza A Infection
MHAA4549A is a human anti‐influenza A monoclonal antibody developed to treat influenza A. We report MHAA4549A serum, nasopharyngeal, and tracheal aspirate pharmacokinetics from a phase 2b study in hospitalized patients with severe influenza A. Patients were randomized 1:1:1 into 3 groups receiving s...
Autores principales: | Deng, Rong, She, Gaohong, Maia, Mauricio, Lim, Jeremy J., Peck, Melicent C., McBride, Jacqueline M., Kulkarni, Priya, Horn, Priscilla, Castro, Aide, Newton, Elizabeth, Tavel, Jorge A., Hanley, William D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7586956/ https://www.ncbi.nlm.nih.gov/pubmed/32621543 http://dx.doi.org/10.1002/jcph.1652 |
Ejemplares similares
-
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of MHAA4549A, a Monoclonal Antibody, plus Oseltamivir in Patients Hospitalized with Severe Influenza A Virus Infection
por: Lim, Jeremy J., et al.
Publicado: (2020) -
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of the Monoclonal Antibody MHAA4549A in Patients With Acute Uncomplicated Influenza A Infection
por: Lim, Jeremy J, et al.
Publicado: (2021) -
4549 Reproducible Informatics for Reproducible Translational Research
por: Gouripeddi, Ram, et al.
Publicado: (2020) -
An Open‐Label Study to Assess the Effect of Itraconazole and Rifampin on Parsaclisib Pharmacokinetics When Administered Orally in Healthy Participants
por: Li, Jia, et al.
Publicado: (2020) -
A Phase 2, Double‐Blind, Placebo‐Controlled Trial to Investigate Potential Drug‐Drug Interactions Between Cannabidiol and Clobazam
por: VanLandingham, Kevan E., et al.
Publicado: (2020)